ArticleApplied biochemistry and biotechnology2026
Purification and Comprehensive Characterization of Two Novel Acidic Glycoproteins from Scorpion with Therapeutic Potential.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Scorpions have long been utilized in traditional medicine for their therapeutic properties, including anti-cancer, analgesic, anti-thrombotic, and immune-modulating properties. This study aimed to optimize extraction conditions, partial purification, structural characterization and biological activity of glycoproteins from the scorpion (Buthus martensii Karsch) body. Under the optimized conditions, the extraction yield of scorpion glycoproteins (SGP's) reached 12.57 ± 0.7%. Subsequently, two novel glycoproteins, SGP-1a and SGP-1b, were isolated through DEAE-52 anion exchange chromatography and Sephadex G-75 gel filtration, with average molecular weights of 46.8 kDa and 10.3 kDa, respectively. Compositional analysis revealed SGP-1a and SGP-1b were rich in monosaccharides (Glu, Gal, Rha) and amino acids (Ser, Lys, Ala, Leu, Arg, Phe), and were characterized as homogeneous acidic protein-bound heteropolysaccharides. FTIR spectrum confirmed that SGP-1a and SGP-1b presence of glycated proteins, β-elimination reaction elucidated that SGP's contained N-glycosidic linkage. According to the CD analysis, SGP-1a contains 7.4% α-helix, 34.1% β-sheet, 13.2% β-turn, 34.6% random coil and SGP-1b contains 4.7% α-helix, 46.8% β-strand, 47.2% random coil. Bioactivity assays demonstrated significant anti-inflammatory activity against COX-2 (IC50: 21.14 ± 1.73 µg/mL for SGP-1a; 18.58 ± 1.54 µg/mL for SGP-1b) Meanwhile, both the SGPs exhibit strong antioxidant activity, the IC
Indexed as
Identifiers
41579258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.